Try our beta test site
9 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND alemtuzumab [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Conditions: CLL;   SLL
Interventions: Drug: Ofatumumab;   Drug: High-Dose Methylprednisolone;   Drug: Alemtuzumab
2 Recruiting Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
Condition: B-cell Chronic Lymphocytic Leukemia
Intervention: Biological: Alemtuzumab
3 Recruiting Lymphoma Bridge Transplant Study
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Bendamustine;   Drug: Carmustine;   Drug: Etoposide;   Drug: Melphalan;   Drug: Cytarabine;   Drug: Alemtuzumab;   Biological: Autologous Stem Cell Transplantation;   Biological: Allogeneic Stem Cell Transplantation;   Drug: Rituximab
4 Recruiting Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
Conditions: Leukemia, Adult T-Cell;   HTLV I Associated T Cell Leukemia;   Adult T-Cell Leukemia (ATL)
Intervention: Biological: IL-15 plus alemtuzumab
5 Recruiting T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Conditions: Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
Interventions: Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
6 Recruiting CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Conditions: Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
7 Recruiting A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Conditions: Ewing Sarcoma;   Gastrointestinal Tumor;   Germ Cell Tumor;   Hepatic Tumor;   Lymphoma;   Wilms Tumor;   Rhabdoid Tumor;   Clear Cell Carcinoma;   Renal Cell Carcinoma;   Melanoma;   Neuroblastoma;   Rhabdomyosarcoma;   Non-rhabdomyosarcoma
Interventions: Drug: alemtuzumab;   Drug: fludarabine;   Drug: sirolimus;   Drug: Busulfan;   Drug: melphalan;   Biological: stem cells
8 Recruiting CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Conditions: Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis;   Sickle Cell Disease;   Beta Thalassemia;   Inborn Errors of Metabolism
Interventions: Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
9 Recruiting Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Condition: Acute Lymphoblastic Leukaemia
Interventions: Drug: VP16;   Radiation: TBI;   Drug: Thiotepa;   Drug: Treosulfan;   Drug: Fludarabine;   Drug: Busulfan

Study has passed its completion date and status has not been verified in more than two years.